HIF-2α Inhibitor Offers Meaningful Improvement in Rare Cancers

The hypoxia-inducible factor-2-α (HIF-2α) inhibitor belzutifan demonstrated clinically meaningful and durable responses in patients with advanced pheochromocytoma and paraganglioma, according to findings from a phase II clinical trial. However, further research will need to confirm its effectiveness and when it should be given to patients relative to other therapies.